Comparison
Abacavir Hypersensitivity C5768819 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between Abacavir Hypersensitivity and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3q13-microdeletion-syndrome-C2931338 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Trigger | Linked to abacavir exposure, often soon after starting it | No drug trigger; present as a congenital condition | High |
| Development | Not a developmental syndrome | May include developmental delay and intellectual disability | High |
| Course | Acute immunologic illness that can be severe | Chronic congenital course, described as moderate | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
New illness after starting abacavir
Timing supports a drug reaction needing urgent clinician review
High
HLA-B*5701 risk identified
This marker informs abacavir risk, not a chromosomal diagnosis
High
Symptoms resolve only after drug withdrawal
Improvement after stopping suggests hypersensitivity, but confirmation is clinical
Moderate
Choose 3q13 Microdeletion Syndrome C2931338 when
Early developmental concerns and congenital features
This pattern fits a genetic disorder rather than a drug reaction
Moderate
Confirmed missing 3q13 material
Genetic evidence supports the syndrome when clinically correlated
High
Lifelong features without medication exposure
Absence of an abacavir trigger argues against hypersensitivity
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify higher risk | Not diagnostic for this syndrome | A risk marker, not proof of an active reaction or genetic syndrome |
| Chromosomal microarray | Not used to diagnose hypersensitivity | May detect missing 3q13 material | A deletion requires clinician correlation and is not a drug-reaction test |
| Medication history | Recent abacavir exposure is essential context | No specific drug association | Exposure history separates an adverse reaction from a congenital disorder |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- May improve after abacavir is stopped, but can be serious and recur with re-exposure
- Factors
- Recognition speed, permanent avoidance, and individual response
3q13 Microdeletion Syndrome C2931338
- Outcome
- A chronic developmental condition with variable support needs
- Factors
- Deletion extent, associated anomalies, and available supports
Time frame: Hours to weeks for the reaction; lifelong for the syndrome
Different causes and courses; precise prognosis is not established here
Complications comparison
| Complication | Presentation |
|---|---|
| Severe systemic reaction | Can become serious and may recur if abacavir is restarted Not a feature of the syndrome Suspected hypersensitivity needs urgent care; do not rechallenge |
| Neurodevelopmental disability | Not characteristic Delays or intellectual disability may occur Severity varies and is not predictable from this summary |
| Congenital anomalies | Not part of the reaction Various congenital features may occur Features are heterogeneous; a finding is not itself a complete diagnosis |
Patient education highlights
- HighAbacavir avoidance
After suspected hypersensitivity, abacavir should not be restarted unless a clinician explicitly directs otherwise.
- HighUrgent symptoms
New fever, rash, breathing, or gastrointestinal symptoms on abacavir need prompt medical advice.
- MediumGenetic result meaning
A 3q13 deletion needs specialist interpretation and does not explain an abacavir reaction.